REPLICATE BIOSCIENCE
Replicate Bioscience creates novel oncology treatments to prevent and reverse drug resistance through a self-replicating RNA platform called SynRGY. By deploying SynRGY technology, the company aims to design novel treatments that prevent the occurrence of drug resistance and create solutions that enhance the effectiveness of many immuno-oncology regimens.
REPLICATE BIOSCIENCE
Industry:
Biotechnology Health Care Life Science Therapeutics
Founded:
2020-01-01
Address:
San Diego, California, United States
Country:
United States
Website Url:
http://www.replicatebioscience.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
46 M USD
Similar Organizations
Acrivon Therapeutics
Acrivon Therapeutics is a precision oncology therapeutics company specializing in drug development through early clinical treatment success.
Aulos Bioscience
Aulos Bioscience is dedicated to revolutionizing patient care in cancer with highly differentiated immuno-oncology therapeutics.
Autobahn Therapeutics
Autobahn Therapeutics is a developer of regenerative medicines to restore hope for people affected by CNS disorders.
Creyon Bio
Reinventing drug development from the ground up to make safe, effective oligonucleotide-based medicines possible on demand.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Foresight Diagnostics
Foresight Diagnostics develops novel technology created to detect cancers earlier from a simple blood draw.
Cultured Decadence
Cultured Decadence creats novel methods to make crustacean products using cell culture and tissue engineering techniques.
Mercy BioAnalytics
Mercy BioAnalytics is a biotechnology company that aims to improve and save the lives of people through the early detection of cancer.
Nurix Therapeutics
Nurix Therapeutics is a biopharmaceutical company that focuses on the development and discovery of small molecule drugs.
Ocelot Bio
Ocelot Bio brings new treatment options to patients with severe liver disease.
Vigil Neuroscience
Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.
Current Advisors List
Current Employees Featured
Founder
Investors List
Apple Tree Partners
Apple Tree Partners investment in Series A - Replicate Bioscience
Apple Tree Partners
Apple Tree Partners investment in Seed Round - Replicate Bioscience
Key Employee Changes
| Date | New article |
|---|---|
| 2022-07-12 | Replicate Bioscience Expands Leadership Team, Appointing Zelanna Goldberg, M.D., as Chief Medical Officer and Mohit Trikha, Ph.D., to Board of Directors |
Official Site Inspections
http://www.replicatebioscience.com
- Host name: 141.193.213.10
- IP address: 141.193.213.10
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Replicate Bioscience"
Replicate Bioscience - Crunchbase Company Profile
Contact Email [email protected] Replicate Bioscience creates novel oncology treatments to prevent and reverse drug resistance through a self …See details»
About Us | Replicate Bioscience
Guided by our team of srRNA experts and with a customizable library of synthetic srRNA vectors and end-to-end development capabilities at our disposal, we are uniquely positioned to …See details»
Replicate Bioscience 2025 Company Profile: Valuation, …
Information on valuation, funding, cap tables, investors, and executives for Replicate Bioscience. Use the PitchBook Platform to explore the full profile.See details»
Replicate Bioscience, Inc. | LinkedIn
Replicate Bioscience, Inc. | 2,862 followers on LinkedIn. The Power of RNA Amplified | Replicate Bioscience is amplifying the power of RNA therapeutics by pioneering novel self-replicating RNA ...See details»
Replicate Bioscience, Inc. Information - RocketReach
Replicate Bioscience is amplifying the power of RNA therapeutics by pioneering novel self-replicating RNA (srRNA) technology. Replicate’s off-the-shelf srRNAs contain two …See details»
Replicate Bioscience, Inc. - Drug pipelines, Patents, Clinical trials ...
Mar 7, 2025 replicatebioscience.com. Startups | Holding Company | 2020 | California, United States | 10-50 | replicatebioscience.com. Last update 07 Mar 2025. Overview. Pipeline. Deal. …See details»
Replicate Bioscience - Overview, News & Similar companies
Apr 22, 2024 View Replicate Bioscience (www.replicatebioscience.com) location in California, United States , revenue, industry and description. Find related and similar companies as well …See details»
Replicate Bioscience - Company Profile - Tracxn
Feb 24, 2025 Replicate Bioscience - Developer of RNA-Based therapeutics for cancer treatment. Raised a total funding of $46M over 2 rounds from 1 investor. Founded by Nathaniel Wang …See details»
Replicate Bioscience - VentureRadar
"Replicate harnesses the body’s natural protein-making power and uses synthetic biology to design unique self-replicating RNAs (srRNAs) that can direct that power to fight disease.See details»
Curia and Replicate Bioscience Enter Strategic
Jun 9, 2022 For more information, visit www.replicatebioscience.com. Contacts Curia Corporate Contact: Sue Zaranek Curia +1 518 512 2111 [email protected]See details»
Replicate Bioscience Initiates a Phase 1 Trial of its Next-Generation ...
SAN DIEGO, Calif., Sept. 12, 2023 – Replicate Bioscience, a clinical-stage company pioneering its novel self-replicating RNA (srRNA) technology to overcome the limitations of current mRNA …See details»
Curia and Replicate Bioscience Enter Strategic ... - Curia Global
ALBANY, N.Y.–(BUSINESS WIRE)–Curia a leading contract research, development and manufacturing organization, and Replicate Bioscience, a company pioneering ways to prevent …See details»
Replicate Bioscience Announces Positive Initial Clinical Results for ...
Feb 14, 2024 Replicate Bioscience, a clinical-stage company pioneering novel self-replicating RNA (srRNA) technology to expand applications of RNA vaccines and other treatments, today …See details»
Replicate Bioscience Announces Publication of First-in-Human …
Feb 7, 2025 Results provide clinical demonstration of best-in-class immunogenicity achieved with an RNA-based platform and good tolerability RBI-4000’s potential to offer a meaningful …See details»
Replicate Bioscience – 2021 OTC Annual Report
Oct 20, 2021 NEW YORK and SAN DIEGO, Sept. 8, 2021 /PRNewswire/ — ATP, a leader in life sciences venture capital, today announced the launch of Replicate Bioscience, a company …See details»
Replicate Bioscience Announces Publication of First-in-Human …
Feb 7, 2025 The Phase I study showed that a single dose of RBI-4000 elicited immune responses that attained a World Health Organization (WHO)-established immune threshold of …See details»
Dosing the first person with srRNA: Advancing a novel technology ...
Sep 28, 2023 Replicate recently announced initiation of a Phase 1 trial of RBI-4000, a self-replicating RNA (srRNA) vaccine developed to protect humans against the rabies virus. Learn …See details»
Replicate Bioscience Initiates a Phase 1 Trial of its Next-Generation ...
SAN DIEGO, Sept. 12, 2023 /PRNewswire/ -- Replicate Bioscience, a clinical-stage company pioneering its novel self-replicating RNA (srRNA) technology to overcome the limitations of …See details»
Establishing Canada’s first large-scale bioinnovation centre
1 day ago The Neptune BioInnovation Centre (NBC), a 51,000 sq ft facility on a 12.3 acre lot in Dartmouth, will offer leasable wet and dry lab space, warehouse and office spaces, and …See details»
Replicate Bioscience Initiates a Phase 1 Trial of its Next ... - BioSpace
Sep 12, 2023 Replicate Bioscience, a clinical-stage company pioneering its novel self-replicating RNA (srRNA) technology to overcome the limitations of current mRNA modalities and expand …See details»